Rational pharmacotherapy in times of pandemic
(Shortened version for ISDB Newsletter of April 2020)
Dr. Dick Bijl,1 Alan Cassels2
1. Former general practitioner-epidemiologist, president International Society of Drug Bulletins. Vredenburgplein 40, NL-3511 WH Utrecht. e-mail; dick.bijl@hetnet.nl
THE HOME TREATMENT OF THE COVID-19 PATIENT
M. Caeran1 , M. Font2
1. Student of Hospital Pharmacy Speciality. Padova University.
2. Pharmacist. UOC Assistenza Farmaceutica Territoriale ULSS 9 Scaligera. Verona. Italy
Several guidelines have recently been published in Italy for the home care of patients with COVID-191-5. They are targeted at physicians working in the primary health care (USCA, on-call doctors, GPs/PLSs).
Among the explored options by the scientific community against the SARS-CoV-2 virus (COVID-19), drugs with antiviral activity stand out. This report assesses the scientific evidence shown by remdesivir (RDV) so far, in the context of the current pandemic.
Among the explored options by the scientific community against the SARS-CoV-2 virus (COVID-19), drugs with antiviral activity stand out. This report assesses the scientific evidence shown by remdesivir (RDV) so far, in the context of the current pandemic.
The current SARS-CoV-2 (COVID-19) coronavirus pandemic is posing many health management challenges with multiple uncertainties. One of the most relevant is focused on the most suitable pharmacological therapy for cure and prophylaxis. Currently, there is no specific drug treatment for COVID-19 that has demonstrated efficacy and safety in high- quality studies (1). However, different options are being proposed from an experimental approach. One of them is the use of chloroquine (CRQ) and its derivatives, basically hydroxychloroquine (HCQ).